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Background: Periodontitis is an inflammatory condition of tooth-
supporting tissues that is usually treated by mechanical removal of plaque
and microorganisms that adhere to teeth. This treatment, known as scal-
ing and root planing, is not optimally effective. Adjunctive therapy with
locally delivered antimicrobials has resulted in improved clinical outcomes
such as probing depth reduction. This article reports on the efficacy and
safety of locally administered microencapsulated minocycline.
Methods: Seven hundred forty-eight (748) patients with moderate to
advanced periodontitis were enrolled in a multi-center trial and random-
ized to 1 of 3 treatment arms: 1) scaling and root planing (SRP) alone; 2)
SRP plus vehicle; or 3) SRP plus minocycline microspheres. The primary
outcome measure was probing depth reduction at 9 months. Clinical
assessments were performed at baseline and 1, 3, 6, and 9 months.
Results: Minocycline microspheres plus scaling and root planing pro-
vided substantially more probing depth reduction than either SRP alone or
SRP plus vehicle. The difference reached statistical significance after the
first month and was maintained throughout the trial. The improved out-
come was observed to be independent of patients’ smoking status, age,
gender, or baseline disease level. There was no difference in the incidence
of adverse effects among treatment groups.
Conclusions: Scaling and root planing plus minocycline microspheres
is more effective than scaling and root planing alone in reducing probing
depths in periodontitis patients. J Periodontol 2001;72:1535-1544.
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Periodontitis is an inflam-matory disease of thesupporting tissues of the
teeth caused by the presence
of subgingival Gram-negative
bacteria, including Porphy-
romonas gingivalis, Bacte- 
roides forsythus, and Trepo-
nema denticola. These patho-
gens coexist with hundreds of
other species in a highly orga-
nized plaque biofilm. The
pathogenesis attributed to
these bacteria may involve: 1)
direct release of proteolytic
enzymes; 2) production of tox-
ins such as lipopolysaccharide
that trigger the expression of
degradable enzymes; and 3)
stimulation of an immune
response resulting in the
release of cytokines from lym-
phocytes and macrophages
that activate degradative path-
ways.1 In susceptible individ-
uals, the ongoing inflamma-
tory process without inter-
vention can cause loss of
supporting tissue and, ulti-
mately, teeth. In addition to
causing local effects, plaque
biofilms can serve as a reser-
voir for the entrance of Gram-
negative bacteria, lipopolysac-
charide, and other soluble
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bacterial components into the general circulation.2
As with chronic infections elsewhere in the body,3-7
associations have been identified between periodon-
titis and various systemic complications including
atherosclerosis/coronary heart disease,8-12 cerebral
vascular ischemia,13,14 low birth weight,15,16 and poor
glycemic control in diabetes.17-20 The United States
Surgeon General’s report on oral health21 recently
made note of these relationships.
Periodontitis affects approximately 15% of Ameri-
cans over the age of 1822 and at least that proportion
in most other countries.23-25 The Surgeon General
reported the incidence in older Americans (65 to 74)
to be 23%.21 Periodontitis is usually treated with scal-
ing and root planing (SRP), which removes subgingi-
val plaque mechanically. This procedure, even when
meticulously performed, improves periodontal status,
but is rarely effective in the complete removal of plaque
or periodontal pathogens.26,27 Given that hundreds of
millions of people worldwide have periodontitis, an
approach that augments the effectiveness of SRP would
have a major impact on managing this disease. Sys-
temic antiobiotics have been prescribed for this pur-
pose, but their widespread use is discouraged because
of the concern over the development of resistant organ-
isms. Locally delivered antimicrobials have also been
used, but not extensively. This is due in part to diffi-
culties in the delivery of some formulations.
A method of microencapsulating minocycline hy-
drochloride in a bioabsorbable polymer (polyglycol-
ide-co-dl lactide) has been developed. The resulting
microspheres are administered in powder form into
diseased periodontal sites. Immediately upon contact
with moisture, the polymer begins to hydrolyze and
release minocycline. The administration results in a
sustained local release of the antibiotic whereby con-
centrations of 340 µg per ml have been measured in
human crevicular fluid after 14 days (unpublished
data). These concentrations far exceed the minimum
inhibitory concentrations (MICs) for periodontal
pathogens. This article reports results from a controlled
Phase 3 clinical trial that examined the efficacy and
safety of minocycline microspheres when used as an
adjunct to scaling and root planing.
MATERIALS AND METHODS
Patient Selection
Eighteen centers participated in this trial. A total of
748 patients with moderate (ADA Type III) to advanced
(ADA Type IV) periodontitis were enrolled. To qualify
for the study, participants were 30 or more years of
age, in good general health, and presented with at
least 4 teeth with probing depths of 6 to 9 mm and
bleeding on probing. Exclusion criteria included: 1)
pregnancy; 2) periodontal therapy within 6 months
prior to enrollment; 3) antibiotic therapy within 3
months prior to enrollment; 4) allergy to tetracyclines;
or 5) chronic therapy within 1 month prior to enroll-
ment with medications that could affect periodontal
status or healing. Patients received a verbal descrip-
tion of the study and provided written informed con-
sent. Human subject review committees of the respec-
tive centers approved the trial.
Study Design
The trial was 9 months in duration and had 3 parallel
arms: 1) control (SRP alone); 2) SRP plus vehicle; and
3) SRP plus minocycline microspheres.¶¶¶ At baseline,
all patients were treated with full-mouth SRP. This treat-
ment was unrestricted with respect to time or use of
local anesthesia. Treatment group assignment was
based on a predetermined randomization plan that
included stratification for smoking status and study
center.
Minocycline microspheres or vehicle was adminis-
tered to all sites with probing depths ≥5 mm. Sites in
the minocycline microspheres plus SRP group were
given a unit dose of 4 mg of drug containing 1 mg of
minocycline and 3 mg of polymer, while sites in the
vehicle group received 3 mg of polymer only. The
microspheres were dispensed subgingivally to the base
of the periodontal pocket by means of a disposable
plastic cartridge affixed to a stainless-steel handle (Fig.
1). Figure 2 shows an electron photomicrograph of
the minocycline microspheres, and a photomicrograph
of the microspheres in cross-section. At 3 and 6
months, patients randomized to either minocycline
microsphere adjunctive therapy or vehicle received an
additional application of the assigned treatment. Data
were collected for all efficacy and safety assessments
at baseline and at 1, 3, 6, and 9 months. Assessments
were performed by the same examiner at each center,
who was blinded with respect to the patient’s treatment.
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Figure 1.
Minocycline microspheres: unit-dose cartridge and handle.
¶¶¶ OraPharma, Inc., Warminster, PA.
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Clinical Measurements and Assessments
Probing depth. Probing depth (PD) was measured from
the gingival margin to the base of the periodontal
pocket using a UNC #15 periodontal probe with 1 mm
markings. Measurements were taken at 6 sites per
tooth and recorded in whole millimeters using a round-
ing down convention if readings fell between mark-
ings. All sites with probing depths measuring ≥4 mm
were measured a second time, and the average of the
2 readings was used as the site-specific probing depth
endpoint. Prior to study initiation, clinicians were trained
and calibrated to measure probing depths. Interexam-
iner reliability was high, with intraclass coefficients and
percent agreement (within 1 mm) values ranging from
0.81 to 0.98 and 87.5% to 98.5%, respectively.
Clinical attachment level (CAL). Clinical attach-
ment level was measured from the cemento-enamel
junction or another fixed reference such as a crown
margin to the base of the periodontal pocket. This
measure was included as a safety assessment because
it is theoretically possible to achieve a favorable prob-
ing depth outcome while actually compromising the
clinical attachment level.
Bleeding on probing (BOP). Following the probing
depth measurement, bleeding was recorded at 6 sites
per tooth as “0” if no bleeding occurred within 10 sec-
onds, and “1” if there was bleeding within 10 seconds.
Oral cavity examination. Oral and perioral hard and
soft tissues were also examined. Findings were
recorded as normal or abnormal at screening, and as
changed or unchanged at subsequent visits.
Vital signs. Vital signs recorded
included blood pressure, tem-
perature, heart rate, and respi-
ration rate.
Adverse events. Adverse
events, both volunteered and
solicited, were documented with
respect to onset, duration, treat-
ment, relation to study medica-
tion, and outcome.
Data Analysis and Statistical
Methods
Primary, secondary, and sub-
group efficacy analyses were all
predetermined, and used the
patient as the experimental unit.
All sites with PD ≥5 mm at base-
line were included in the analy-
ses. The primary outcome mea-
sure was the average change in
PD from baseline to 9 months.
Site-specific PD changes from
baseline were averaged to pro-
vide a mean change from base-
line for each patient. To test for differences among the
groups, patients’ mean changes were analyzed using
an analysis of covariance model adjusted for study
site, baseline response, age, disease severity, and
smoking status. Results presented in this paper are for
adjusted means. All treatment comparisons were made
using 2-sided tests with a 95% confidence interval.
Analysis of covariance (ANCOVA) models were fitted
using PROC GLM.### The F-tests based on Type III sums
of squares**** was used for all hypothesis testing.
Clinical response was a secondary outcome mea-
sure, and was defined as the percentage of treatment
sites that showed a prespecified level of improvement
in PD at 9 months relative to baseline. The clinical
response levels selected for this study were 1 and 2
mm since they are commonly used by clinicians to
monitor disease progression. For each level, the
patient-specific endpoint was computed as the per-
centage of treatment sites responding.
Bleeding on probing was also selected as a sec-
ondary outcome measure since it is a common
approach for assessing the inflammatory state of peri-
odontal sites. The percentage of treatment sites that
demonstrated bleeding on probing was determined for
each patient, and the average change from baseline
was calculated. Clinical attachment level was assessed
by calculating patient mean changes from baseline.
Odds ratios with 95% confidence intervals were cal-
culated post hoc to compare SRP plus minocycline
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Figure 2.
Left: Electron photomicrograph of minocycline microspheres. Right: Cross-sectional photomicrograph of
microspheres showing minocycline HCI particles (arrow).
###   SAS Institute, Inc., Cary, NC.
**** Version 6.12, SAS Institute, Inc.
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microspheres and SRP alone groups for reducing mean
PD to <5 mm. An additional post hoc analysis com-
pared the 2 groups for PD changes in patients’ molar
teeth. The ANCOVA model previously described was
used for this analysis. Demographic and safety results
(except CAL) were evaluated using descriptive statis-
tics. In this study, the intent-to-treat sample population
included all randomized patients. Last Observation
Carried Forward and Worst Observation
Carried Forward imputations were
applied to missing data for each of the
principal variables.
The relative responses to the study
treatment were consistent across the
investigators for each efficacy variable,




Of the 748 patients enrolled in the study
at the baseline visit, 250 were random-
ized to SRP alone, 249 to SRP plus vehi-
cle, and 249 to SRP plus minocycline
microspheres. A total of 229 (91.6%),
230 (92.4%), and 237 (95.2%) patients
in the control, vehicle, and minocycline
microsphere groups, respectively, com-
pleted the study. All randomized patients
were analyzed for efficacy and safety.
Demographic and baseline charac-
teristics (Table 1) were similar across
the 3 treatment groups. Most patients
were male (54.8%) and Caucasian
(75.8%). Mean ages were 47.7, 47.2,
and 49.1 years (range, 29 to 79 years)
for the control, vehicle, and minocycline
microsphere patients, respectively.
Severity of periodontal disease was
moderate in 61.2% and advanced in
38.8% of patients, with similar distribu-
tion across treatment groups. Smokers
were equally distributed across treat-
ment groups and comprised 36.2% of
total enrollment. Baseline mean PD,
CAL, and number of treated sites were
also similar for each treatment group. In
this study, we evaluated an average of
30.7 sites per patient, resulting in a total
of 22,987 sites. After 1 month of treat-
ment, patients receiving SRP plus
minocycline microspheres had a signif-
icantly greater mean reduction in PD
when compared with vehicle and con-
trol groups (P <0.001). As shown in Fig-
ure 3, superiority for the SRP plus
minocycline microsphere group was maintained
throughout the study. At 9 months, the reduction in
mean PD was 1.08 (SE 0.04) mm for the control
group, 1.00 (SE 0.04) mm for SRP plus vehicle, and
1.32 (SE 0.04) mm for the SRP plus minocycline
microsphere group. The difference between SRP plus
minocycline microspheres and the other groups after
9 months was statistically significant at P <0.001.
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Table 1.
Demographic and Baseline Characteristics of All
Randomized Patients
Minocycline
Descriptive SRP Vehicle Microspheres
Characteristic Statistic (250) (249) (249)
Gender
Male n (%) 132 (52.8) 144 (57.8) 134 (53.8)
Female n (%) 118 (47.2) 105 (42.2) 115 (46.2)
Age (years) n 250 249 249
≥50 n (%) 167 (66.8) 168 (67.5) 142 (57.0)
<50 n (%) 83 (33.2) 81 (32.5) 107 (43.0)
Mean 47.7 47.2 49.1
SD 9.7 10 10.2
Median 47 46 48
Range (29-76) (29-79) (29-76)
Race and ethnicity
Caucasian n (%) 191 (76.4) 181 (72.7) 195 (78.3)
Black n (%) 29 (11.6) 39 (15.7) 30 (12)
Asian n (%) 11 (4.4) 9 (3.6) 9 (3.6)
Hispanic n (%) 14 (5.6) 17 (6.8) 12 (4.8)
Other n (%) 5 (2.0) 3 (1.2) 3 (1.2)
Disease severity
Moderate n (%) 156 (62.4) 156 (62.7) 146 (58.6)
Advanced n (%) 94 (37.6) 93 (37.3) 103 (41.4)
Smoking status
Yes* n (%) 91 (36.4) 90 (36.1) 90 (36.1)
No n (%) 159 (63.6) 159 (63.9) 159 (63.9)
Number of baseline n 250 249 249
treatment sites Mean 29.5 31.7 31
SD 17.9 19.9 20.3
Median 24 27 26
Range (5-114) (4-137) (5-108)
Average probing n 250 249 249
depth Mean 5.8 5.9 5.8
SD 0.4 0.5 0.4
Median 5.7 5.7 5.7
Range (5.2-8.4) (5-7.8) (5.2-7.5)
Average clinical n 250 249 249
attachment level Mean (SD) 5.43 (1.44) 5.38 (1.43) 5.39 (1.38)
Median 5.6 5.5 5.5
Range (2.11-10.19) (2.13-9.50) (2.21-9.05)
* Used tobacco product within the last 6 months.
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The mean percentage of sites per patient with PD
reductions of ≥1 mm was 60.07, 57.33, and 67.94 for
control, SRP plus vehicle, and SRP plus minocycline
microsphere groups, respectively, as presented in Table
2. Differences between SRP plus minocycline micro-
spheres and the other 2 groups were statistically sig-
nificant at P <0.001. The mean percentage of sites with
PD reductions of ≥2 mm for the 3 respective groups
was 32.87, 28.98, and 40.52. Differences between the
SRP plus minocycline microsphere group and the other
2 groups were also significant at P <0.001.
Overall reduction in BOP was similar among treat-
ment groups (data not shown). However, post hoc
analysis of a subgroup of patients with more advanced
disease (baseline mean PD ≥6 mm) showed signifi-
cant differences among groups. In these patients, the
percentage reduction in bleeding sites for the control
group was 19.80 (SE 2.44), compared with 18.11%
(SE 2.17) for SRP plus vehicle and 26.04% (SE 2.17)
for SRP plus minocycline microspheres. These differ-
ences were significant at P = 0.005 and P = 0.047,
respectively.
Results for subgroup analyses are presented
only for SRP alone and SRP plus minocycline
microsphere groups since the results for SRP
plus vehicle and SRP alone were similar. Fig-
ure 4 shows mean PD reductions at 9 months
for patient subgroups based on baseline PD.
For patients with mean baseline PD ≥6 mm,
mean reduction was 1.05 (SE 0.10) mm for
the SRP group and 1.46 (SE 0.09) mm for SRP
plus minocycline microspheres. The difference
between groups (0.41 mm) was significant at
P ≤0.01. For patients with baseline PD ≥7 mm,
mean reduction was 0.98 (SE 0.29) mm for
SRP compared with 1.99 (SE 0.31) mm for
SRP plus minocycline microspheres. The dif-
ference between treatment groups was the
greatest in these patients (1.01 mm), and
despite the small sample size, a P value of 0.06
suggests that this sample is representative of
the population. Figure 5 shows the percentage
difference in PD reduction between these
patient groups. For patients with mean PD ≥5
mm, ≥6 mm, and ≥7 mm, the percentage dif-
ferences in favor of SRP plus minocycline
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Table 2.
Summary of Clinical Response Level Using Baseline Treatment Sites
Patient’s
Percent Treatment Comparison
of Baseline Minocycline (P Values)
Treatment Descriptive SRP Vehicle Microspheres Minocycline Microspheres  Versus
Sites With Statistic (250) (249) (249) SRP Vehicle
PD reduction N 250 249 249 <0.001* <0.001*
≥1 mm LS mean (SE) 60.07 (1.40) 57.33 (1.40) 67.94 (1.40)
at month 9 Mean (SD) 64.18 (28.30) 61.32 (27.41) 71.90 (25.90)
Median 67.96 62.16 76.92
Range (0,00, 100.00) (0.00, 100.00) (0.00, 100.00)
PD reduction N 250 249 249 <0.001* <0.001*
≥2 mm LS mean (SE) 32.87 (1.39) 28.98 (1.39) 40.52 (1.39)
at month 9 Mean (SD) 36.62 (28.09) 32.75 (27.35) 44.63 (28.73)
Median 31.58 25.00 42.11
Range (0.00, 100.00) (0.00, 100.00) (0.00, 100.00)
* P value from ANCOVA for the null hypothesis that the response is equal between the 2 treatment groups.
Figure 3.
Average probing depth reduction (adjusted means) from baseline.
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microspheres were 22.2, 39.0, and 103.1,
respectively. Table 3 presents odds ratios com-
paring minocycline microsphere adjunctive
therapy with SRP alone for reducing mean PD
to <5 mm in patients with mean baseline PD ≥5
mm and ≥6 mm. Odds ratios were significant
at 1.59 and 2.86 for patients with baseline PD
≥5 mm and ≥6 mm, respectively. With an odds
ratio of 2.86, minocycline microsphere ther-
apy would be nearly 3 times more likely to
reduce mean probing depths from ≥6 mm to <5
mm than SRP alone.
Results for predetermined subgroups based
on smoking status, age, and gender are pre-
sented in Figure 6. The difference in PD reduc-
tions between treatments in both smokers and
non-smokers was significant (P ≤0.01), with a
greater difference between treatments in smok-
ers (0.29 mm) than in non-smokers (0.20 mm).
The difference between treatment groups was
significant in older (>50) and younger (≤50)
patients (P ≤0.05), but was greater in patients
>50 years (0.33 mm versus 0.18 mm in patients ≤50
years). Minocycline microsphere therapy worked sim-
ilarly in men and women, and at 9 months reached sta-
tistical significance in each (P ≤0.004). An additional
predetermined analysis was conducted for patients with
a history of cardiovascular disease (data not shown).
Despite a small sample size (n = 36), the difference in
PD reduction between SRP plus minocycline micro-
spheres and SRP alone groups was highly significant
(P <0.001) in favor of minocycline microspheres.
Results for molar teeth are presented in Figure 7.
Probing depth reduction was significantly greater for the
SRP plus minocycline microsphere group at all exam-
inations, and at 9 months was 0.99 (SE 0.05) mm for
SRP alone compared with 1.26 (SE 0.05) mm for SRP
plus minocycline microspheres. The numerical differ-
ence in PD reduction between the 2 groups at 9 months
(0.27 mm) was slightly greater than the difference
observed for all teeth.
Safety
Adverse events were reported by 62.4%, 71.9%, and
68.3% of patients in the control, vehicle, and combi-
nation therapy groups, respectively. The incidence of
these adverse events was similar among treatment
groups. The most common adverse events (Table 4)
included headache, dental infection, increased peri-
odontitis, tooth sensitivity, tooth caries, dental pain,
gingivitis, and stomatitis.
No clinically significant changes in vital signs or oral
hard or soft tissues were noted in these studies. All
groups experienced a mean gain in clinical attachment
at 9 months, but the minocycline microsphere group
showed a greater gain.
1540
Table 3.
Odds Ratio for Reducing Patient Mean
Probing Depth to <5 mm; Minocycline
Microspheres Versus SRP Alone
Baseline 95%
Probing Depth Odds Ratio N Confidence Interval
≥5 1.59 499 1.08, 2.35
≥6 2.86 141 1.45, 5.66
Figure 4.
Mean probing depth reduction at 9 months based on baseline probing depth.
Figure 5.
Percent difference in probing depth reduction at month 9 by baseline
probing depth.
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DISCUSSION
The objectives of this study were to: 1) determine
whether the administration of minocycline micro-
spheres would enhance the therapeutic effect of scal-
ing and root planing in patients with chronic peri-
odontitis, and 2) determine whether the compound
was safe and well tolerated. Our
results show that adjunctive treat-
ment with SRP plus minocycline
microspheres reduces probing
depths significantly more than
SRP alone. Adjunctive therapy
with minocycline microspheres
showed a 22% greater therapeu-
tic effect than the commonly
practiced scaling and root plan-
ing, while, as anticipated, the
vehicle had no potentiating effect.
The results reported here are at
the higher end of the range of
probing depth reductions reported
for other locally delivered agents,
which included sustained release
of doxycycline28 and chlorhexi-
dine.29
Because clinically relevant
assessments are not always pos-
sible when analyzing overall mean
differences between treatment
groups,30 this trial was specifically
designed for such assessments. A
parallel design, rather than split
mouth, that treated all sites with
PD ≥5 mm was employed and yielded suffi-
cient numbers of sites and teeth to evaluate
specific local variances that can have a pro-
found effect on therapeutic outcomes. This
design also allowed for testing the ease of
use of the delivery system. Administering
minocycline microspheres to over 7,500 sites
provided a wide distribution of the number
of sites treated in each patient. This enabled
us to detect whether there was a trend toward
a fatigue factor that affected efficacy in
patients with numerous sites treated.
“Clinical response” has become a com-
mon means for presenting clinically rele-
vant data. In particular, the 2 mm threshold
is a level clinicians use to monitor disease
progression and evaluate therapeutic suc-
cess. Patients’ mean percentage of treat-
ment sites with probing reductions ≥2 mm
was significantly higher for the SRP plus
minocycline microsphere group. In addition
to threshold reduction levels, reducing prob-
ing depths to less than 5 mm is also impor-
tant. Odds ratio calculations revealed that SRP plus
minocycline microspheres was almost 3 times as likely
as scaling and root planing alone to reduce mean
probing depths to <5 mm in patients with baseline
probing depths ≥6 mm. This finding may have a sig-
nificant impact on the course of therapy, since a 5 mm
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Figure 6.
Probing depth reduction at 9 months based on gender, age, and smoking status.
Figure 7.
Average probing depth reduction (adjusted means) from baseline: molar teeth.
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probing depth is often considered in the decision to
proceed to further therapy such as surgery.
SRP plus minocycline microsphere therapy was
more effective than SRP plus vehicle or SRP alone in
all subgroups. Substantially greater treatment effects
were noted in subgroups with increased baseline prob-
ing depths. This observation was not unexpected. Since
scaling and root planing has been shown to be less
efficient in removing plaque and microorganisms from
deeper sites,31 a locally delivered antibiotic should be
particularly effective in these sites. Other work has
reported similar findings.32
In this study, non-smokers showed greater improve-
ment than smokers. This is in agreement with prior
reports of a reduced response to periodontal therapy
in smokers.33 Smokers in the SRP plus minocycline
microsphere group, however, showed significantly
greater probing depth reduction than smokers in the
SRP alone group. In fact, the proportional treatment
effect for adjunctive therapy with minocycline micro-
spheres was greater in smokers. SRP plus minocycline
microspheres showed a 32.2% increase in mean prob-
ing depth over scaling and root planing for smokers,
compared to 16.0% in non-smokers. One possible
explanation for the enhanced treatment effect of SRP
plus minocycline microspheres in smokers is the
antimetalloproteinase properties of minocycline that
could counteract the increased protease activity asso-
ciated with smoking. The effects of nicotine on met-
alloproteinase activity are well known. It has been
shown, for example, that nicotine can increase colla-
genase activity in vitro using human gingival fibro-
blasts.34 In the smoker’s lung, it was shown that the
inhibitory effect of α1-antitrypsin on elastase released
from neutrophils is compromised.35 A second possi-
ble explanation is that smokers may harbor higher pro-
portions of certain periodontal pathogens,36 making
them more likely to benefit from the antibiotic.
Patients of all ages showed significantly more prob-
ing depth reduction with adjunctive minocycline
microsphere therapy compared with SRP alone, but
the treatment effect was proportionally greater in older
patients. As Figure 6 shows, the treatment effect was
more pronounced in patients over 50 due to that
group’s poorer response to scaling and root planing
when compared with younger patients. The reason for
this is unclear since age does not seem to have an
effect on healing following periodontal therapy.37 The
observation that adjunctive therapy with minocycline
microspheres was more effective in smokers and older
patients may be particularly significant since peri-
odontitis is more prevalent in these individuals, and
because they are at risk for several systemic diseases.
It is important to test this therapy in other groups that
have periodontitis, such as diabetic and immunosup-
pressed individuals. Patients with a history of cardio-
vascular disease should probably be included as well,
since our results suggest a greater effect with adjunc-
tive minocycline microsphere therapy in that group
versus SRP alone, albeit in a very small sample. Such
studies are currently being planned.
The analysis on molar teeth showed that adjunctive
SRP plus minocycline microsphere therapy maintained
its effectiveness over SRP alone. This is clinically rel-
evant since it has been shown that molar teeth do not
respond as well as single-rooted teeth to mechanical
therapy.38 It would be of interest to further dissect this
analysis by subgrouping sites in molar teeth based on
baseline PD.
In this study, bleeding on probing was reduced to a
greater extent in the SRP plus minocycline micros-
phere group (data not shown). Differences between
treatment groups reached statistical significance only
in patients with advanced disease. This is under-
standable given the insensitivity of assessing bleeding
as present or absent. In addition, the assessment itself
is quite subjective since bleeding can be influenced by
probing pressure as well as the inflammatory state of
the soft tissue.
The therapeutic benefit of minocycline microsphere
therapy was accomplished without concern for sys-
temic effects of minocycline. This statement is sup-
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Table 4.





Event (N = 250) (N = 249) (N = 248)
Total number of AE 543 589 594
Number (%) of patients 156 (62.4) 179 (71.9) 170 (68.3)
Periodontitis 64 (25.6) 70 (28.1) 54 (21.7)
Tooth sensitivity 30 (12.0) 34 (13.7) 39 (15.7)
Tooth caries 23 (9.2) 28 (11.2) 32 (12.9)
Infection 20 (8.0) 24 (9.6) 27 (10.8)
Dental pain 22 (8.8) 22 (8.8) 24 (9.6)
Gingivitis 18 (7.2) 22 (8.8) 24 (9.6)
Headache 18 (7.2) 29 (11.6) 17 (6.8)
Stomatitis 21 (8.4) 17 (6.8) 12 (4.8)
Flu syndrome 8 (3.2) 16 (6.4) 10 (4.0)
Dental infection 10 (4.0) 9 (3.6) 11 (4.4)
Accidental injury 8 (3.2) 9 (3.6) 6 (2.4)
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ported by results from a recent combined pharmaco-
kinetic and bacterial resistance trial which showed
relatively little systemic absorption of minocycline fol-
lowing local administration with minocycline micro-
spheres, and no development of resistant bacteria in
fecal samples.39,40 The means for achieving the effi-
cacy results with adjunctive minocycline microsphere
therapy observed in this study could be attributed to
a number of activities associated with the tetracycline
family of drugs. It is likely, however, that the antimi-
crobial activity of minocycline played a major role, as
evidenced by a separate independent study that
showed minocycline microspheres to be highly effec-
tive against local periodontal pathogens.41
Supplementing the mechanical removal of subgin-
gival microorganisms could have implications beyond
protecting teeth, and includes reducing risk for sys-
temic complications. Indeed, reports of associations
between periodontitis and systemic complications are
common. A review13 of one study reported an asso-
ciation with fatal heart disease and stroke, with inci-
dence odds ratios of 1.9 and 2.8, respectively, after
adjusting for known risk factors. A study by Wu et
al.14 reported relative risks of 2.11 for incident non-
hemorrhagic stroke in patients with periodontitis, and
1.66 for total cerebrovascular accident. Associations
were also shown with hematological changes consid-
ered to be risk factors for cardiovascular disease.
Specifically, patients with periodontitis have higher
white blood cell counts43 and higher levels of von
Willebrand factor,42 fibrinogen,43 and acute-phase reac-
tants.44 Associations with systemic disorders other
than cardiovascular disease have also been shown.
Insulin requirements in type 1 and type 2 diabetics
were reduced following treatment for periodontal dis-
ease which included systemic antibiotic administra-
tion.17-20 A case-control study of pregnant or post-
partum mothers showed that those with periodontitis
were more than 7 times as likely to have a preterm
low birth weight infant.15 Evidence from these studies,
coupled with a better understanding of the pathogen-
esis of periodontitis, suggests that this oral infection
of epidemic proportion may be associated with sev-
eral systemic complications.
The user friendliness of a locally delivered antimi-
crobial warrants some discussion in efficacy trials, par-
ticularly when the number of sites treated is large. Clin-
icians participating in this study found minocycline
microspheres easy to administer, and were able to treat
an average of approximately 30 sites per patient with-
out appreciably prolonging the scaling and root plan-
ing visit. There was no evidence of a fatigue factor
that impacted efficacy since there were no differences
in PD reduction between patients with higher versus
lower numbers of treated sites (data not shown). Since
the powder, composed of minocycline microspheres,
begins to hydrolyze upon contact with moisture, it
immediately becomes bioadhesive and self-retentive.
These attributes would be likely to favorably impact
efficacy.
In conclusion, scaling and root planing plus minocy-
cline microspheres provided significantly greater prob-
ing depth reduction than scaling and root planing alone.
The therapeutic effect was even more pronounced in
patients with compromising conditions at both sys-
temic and local levels. Considering the limitations of
scaling and root planing shown in this and other stud-
ies, along with evolving evidence that minimizing oral
infections may contribute to patients’ general well-
being, it would appear that the use of locally delivered
antimicrobial agents should be incorporated as part of
an optimal non-surgical therapeutic regimen.
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